The N Terminus of the Retinoblastoma Protein Inhibits DNA Replication Via a Bipartite Mechanism Disrupted in Partially Penetrant Retinoblastomas
Overview
Affiliations
The N-terminal domain of the retinoblastoma (Rb) tumor suppressor protein (RbN) harbors in-frame exon deletions in partially penetrant hereditary retinoblastomas and is known to impair cell growth and tumorigenesis. However, how such RbN deletions contribute to Rb tumor- and growth-suppressive functions is unknown. Here we establish that RbN directly inhibits DNA replication initiation and elongation using a bipartite mechanism involving N-terminal exons lost in cancer. Specifically, Rb exon 7 is necessary and sufficient to target and inhibit the replicative CMG helicase, resulting in the accumulation of inactive CMGs on chromatin. An independent N-terminal loop domain, which forms a projection, specifically blocks DNA polymerase α (Pol-α) and Ctf4 recruitment without affecting DNA polymerases ε and δ or the CMG helicase. Individual disruption of exon 7 or the projection in RbN or Rb, as occurs in inherited cancers, partially impairs the ability of Rb/RbN to inhibit DNA replication and block G1-to-S cell cycle transit. However, their combined loss abolishes these functions of Rb. Thus, Rb growth-suppressive functions include its ability to block replicative complexes via bipartite, independent, and additive N-terminal domains. The partial loss of replication, CMG, or Pol-α control provides a potential molecular explanation for how N-terminal Rb loss-of-function deletions contribute to the etiology of partially penetrant retinoblastomas.
The CMG helicase and cancer: a tumor "engine" and weakness with missing mutations.
Xiang S, Reed D, Alexandrow M Oncogene. 2022; 42(7):473-490.
PMID: 36522488 PMC: 9948756. DOI: 10.1038/s41388-022-02572-8.
Ford K, Panwala R, Chen D, Portell A, Palmer N, Mali P Cell Syst. 2021; 12(7):716-732.e7.
PMID: 34051140 PMC: 8298269. DOI: 10.1016/j.cels.2021.05.002.
TGFβ1 Cell Cycle Arrest Is Mediated by Inhibition of MCM Assembly in Rb-Deficient Conditions.
Nepon-Sixt B, Alexandrow M Mol Cancer Res. 2018; 17(1):277-288.
PMID: 30257992 PMC: 6318023. DOI: 10.1158/1541-7786.MCR-18-0558.
Imperatore V, Pinto A, Gelli E, Trevisson E, Morbidoni V, Frullanti E Eur J Hum Genet. 2018; 26(7):1026-1037.
PMID: 29662154 PMC: 6018773. DOI: 10.1038/s41431-017-0054-6.
The Human Replicative Helicase, the CMG Complex, as a Target for Anti-cancer Therapy.
Seo Y, Kang Y Front Mol Biosci. 2018; 5:26.
PMID: 29651420 PMC: 5885281. DOI: 10.3389/fmolb.2018.00026.